ARID1A is altered in 36.29% of ovarian endometrioid adenocarcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA1 is altered in 5.69% of ovarian endometrioid adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 4 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 2 are closed. Of the trials that contain BRCA1 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [3].

BRCA2 is altered in 6.15% of ovarian endometrioid adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 4 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 2 are closed. Of the trials that contain BRCA2 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [3].

MLH1 is altered in 2.44% of ovarian endometrioid adenocarcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 7.63% of ovarian endometrioid adenocarcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 8.87% of ovarian endometrioid adenocarcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 1.79% of ovarian endometrioid adenocarcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 3.75% of ovarian endometrioid adenocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is altered in 4.24% of ovarian endometrioid adenocarcinoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 22.92% of ovarian endometrioid adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].